Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized CSC-based drug therapy in newly diagnosed glioblastoma
NCT05380349Phase 1Recruiting
- Sponsor
- Swedish Health Services
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioblastoma (GBM), sponsored by Swedish Health Services. Primary endpoint: Safety of CSC/HTS-based combination drug therapy at 24 months. Started Apr 2024; status: recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05380349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380349.